GLP-1 Weight-Loss Drugs: What Happens When People Stop

Level: C1

Printable: Student handout (PDF) | Teacher’s key (PDF)

Reading

On 21 March 2026, the day after a key patent on semaglutide expired in India, several Indian drug makers began selling generic versions of it. Branded semaglutide had cost roughly 8,800 to 11,000 rupees a month there, while NATCO Pharma listed its lowest-priced generic at 1,290 rupees. Semaglutide, sold as Ozempic and Wegovy, belongs to the GLP-1 class: medicines that copy a gut hormone which reduces appetite and helps control blood sugar. Tirzepatide acts on a second hormone, GIP, as well. The US has also approved GLP-1 pills, including orforglipron, which was discovered by the Japanese company Chugai. Cheaper and easier forms sharpen a question that trials have only begun to answer: what happens when people stop?

The weight loss itself is well established. The efficacy of these drugs has been measured in large randomized trials against a placebo, an inactive treatment. In STEP 1, 1,961 adults with obesity, or with overweight and at least one weight-related comorbidity such as high blood pressure, lost an average of 14.9 percent of their body weight over 68 weeks on semaglutide, compared with 2.4 percent on placebo. In SURMOUNT-1, the highest dose of tirzepatide produced an average loss of 20.9 percent at 72 weeks, and in a direct comparison published in 2025, tirzepatide led semaglutide by 20.2 to 13.7 percent. Doses are raised in steps over several weeks, a process called dose escalation, partly to limit the most common side effects: nausea, vomiting, and diarrhea.

Benefits beyond weight are harder to judge, partly because of how numbers are reported. The SELECT trial followed 17,604 adults with overweight or obesity and existing heart disease, but not diabetes, for more than three years. Heart attacks, strokes, and cardiovascular deaths occurred in 6.5 percent of the semaglutide group, compared with 8.0 percent of the placebo group. Headlines reported a 20 percent reduction in risk, which is the relative figure; the absolute difference was 1.5 percentage points. Both numbers are correct, but they leave different impressions. The trial also showed a cost: 16.6 percent of participants stopped semaglutide because of adverse events, mostly digestive problems, about twice the rate on placebo.

Stopping has been tested directly. In an extension of STEP 1, researchers followed 327 participants for a year after treatment ended. Those who had taken semaglutide regained 11.6 percentage points of the 17.3 percent they had lost, about two-thirds, although this was an exploratory analysis. SURMOUNT-4 used a stronger design. After 36 weeks on tirzepatide, 670 adults were randomly assigned either to keep taking it or to switch to placebo. Over the next year, the placebo group regained 14 percent of their body weight, while the tirzepatide group lost a further 5.5 percent. In both studies, much of the improvement in heart-related risk factors, such as blood pressure, was also reversed.

A review in The BMJ in January 2026, led by researchers at the University of Oxford, combined 37 studies with 9,341 adults. After weight-loss medicines were stopped, weight returned at an average of 0.4 kilograms a month, and the authors estimated a return to baseline, the starting weight, after about 1.7 years. For semaglutide and tirzepatide, regain was faster, at about 0.8 kilograms a month. These are averages, and some people kept weight off. A later analysis in eClinicalMedicine projected that regain would reach a plateau at around 75 percent of the weight lost, but, as a nutrition researcher at the University of Surrey pointed out, that figure is an extrapolation beyond the year of data actually observed.

Outside trials, stopping is common. In a study of 125,474 US adults published in JAMA Network Open in 2025, 64.8 percent of those without type 2 diabetes ended treatment within a year, compared with 46.5 percent of those with it. The risk of discontinuation was higher with digestive side effects and smaller weight loss, and lower with higher income. These associations suggest that adherence depends partly on cost and tolerability, not only on motivation. The World Health Organization, in its December 2025 guideline, describes obesity as a chronic, relapsing disease and supports GLP-1 drugs as long-term treatment. It made this a conditional recommendation, based on moderate-certainty evidence, and noted that data on stopping and on maintenance doses are limited.

This is where the Indian generics matter. If the benefit lasts only as long as the regimen does, the price of years of treatment matters more than the price of one month. Lower prices could make long-term use possible for far more people, but the WHO has also warned about falsified and substandard versions sold online, a risk that may grow with demand. The next question for researchers is practical: whether people who have lost weight can keep most of it off on a lower, cheaper maintenance dose.

Vocabulary

Each word has a frequency score, a rank, and a tag. The score shows how common the word is in modern English: higher means more common, and each full point means roughly ten times more common. The rank is the word’s position on a list of about 321,000 English word forms, from most to least common. The tag shows where you are most likely to meet the word: Current, Formal, Literary, or Dated. The paragraph number shows where the word first appears in the reading. The labels are information, not instructions. Deciding which words are worth your time is up to you. How to read the scores, ranks, and tags.

Several Indian drug makers began selling generic versions of it.
The pharmacist offered me a generic painkiller that cost half as much.

The efficacy of these drugs has been measured in large randomized trials.
The trial measured the efficacy of the vaccine.

Their efficacy has been measured in large randomized trials against a placebo.
Half of the group received a placebo.

Participants had obesity, or overweight and a weight-related comorbidity such as high blood pressure.
Diabetes is a common comorbidity of obesity.

Doses are raised in steps over several weeks, a process called dose escalation.
The escalation of the conflict alarmed the region.

Many participants stopped semaglutide because of adverse events, mostly digestive problems.
Adverse weather delayed the flight.

The authors estimated a return to baseline, the starting weight, after about 1.7 years.
We recorded each runner’s heart rate as a baseline before training began.

One analysis projected that regain would reach a plateau at around 75 percent of the weight lost.
Sales reached a plateau in the third year.

That figure is an extrapolation beyond the year of data actually observed.
Their forecast for next year is an extrapolation from three years of sales.

The risk of discontinuation was higher with digestive side effects and smaller weight loss.
The discontinuation of the night bus upset local workers.

Adherence depends partly on cost and tolerability, not only on motivation.
Adherence to the diet was low in the study.

The WHO describes obesity as a chronic, relapsing disease.
She has chronic back pain.

It made this a conditional recommendation, based on moderate-certainty evidence.
The offer is conditional on a medical check.

If the benefit lasts only as long as the regimen does, long-term price matters.
The doctor set a strict exercise regimen.

The WHO has warned about falsified and substandard versions sold online.
The building was closed for substandard wiring.

Activity Page

Open the activity page in a new tab

Speed Challenge

Answer 12 questions against the clock. Every wrong answer adds 5 seconds, and the lowest score wins. Open the speed challenge in a new tab.

Comprehension Questions

What happened in India in March 2026, and why does the writer begin with it?
Summarize the weight-loss results in the second paragraph. Which comparison is the most direct, and why?
Why are doses raised in steps, and which side effects are most common?
Explain the difference between the relative and the absolute figures from the SELECT trial.
Compare the designs and the results of the STEP 1 extension and SURMOUNT-4.
What did the BMJ review find, and which limits of its findings does the writer mention?
Why does the writer call the 75 percent figure an extrapolation, and why does that matter?
Which factors were linked to stopping treatment in the JAMA Network Open study, and what does the writer conclude from them?
Why, according to the writer, does the price of years of treatment matter more than the price of one month? How convincing is this argument?

IELTS-Style Questions

True, False, or Not Given: “In SURMOUNT-4, people who switched to placebo regained all of the weight they had lost within a year.” Explain your answer using evidence from the reading.
Yes, No, or Not Given: “The writer believes that headlines about the SELECT trial reported a false figure.” Explain your answer using evidence from the reading.
Author’s purpose: Why does the writer end with a question about maintenance doses rather than a conclusion about who should take these drugs?

AI Discussion Prompt

I just read a C1 English lesson called GLP-1 Weight-Loss Drugs: What Happens When People Stop. It began with generic semaglutide going on sale in India in March 2026, then covered trial results for semaglutide and tirzepatide, the difference between relative and absolute risk in the SELECT trial, what happened when people stopped treatment in the STEP 1 extension and SURMOUNT-4, a 2026 BMJ review on weight regain, real-world data on how often people stop, and the WHO’s conditional guideline. I am an advanced English learner at about C1 level. Please have a balanced conversation with me about the evidence and the questions of cost and fairness, presenting more than one perspective. Do not give me medical advice and do not ask about my own health, weight, or medicines. Ask one question at a time. Encourage me to use words like efficacy, baseline, extrapolation, adherence, and conditional. Respond to my ideas first, then briefly point out one or two language errors or more precise word choices.

AI Vocabulary Prompt

I want to practice vocabulary from a lesson about GLP-1 weight-loss drugs. Please quiz me on the following words one at a time, using a mix of question types: multiple choice, true/false, and sentence completion. Give me feedback after each answer before moving on, and bring back the words I miss later. Here are the words: generic, efficacy, placebo, comorbidity, escalation, adverse, baseline, plateau, extrapolation, discontinuation, adherence, chronic, conditional, regimen, substandard.

Discussion Questions

How are weight-loss drugs discussed in the news or on social media where you live?
When you see a health headline with a percentage, what do you check before you believe it?
Why might a relative figure such as “20 percent lower risk” sound more impressive than an absolute one?
Why is a randomized trial stronger evidence than following people who chose to stop on their own?
Many medicines for blood pressure or cholesterol are taken for life. Should obesity drugs be viewed in the same way? Why or why not?
The JAMA Network Open study linked higher income to staying on treatment. What does this suggest about fairness in health care?
Should public health systems pay for long-term treatment? If so, for whom, and for how long?
What are the benefits and the risks when the patent on a popular medicine expires?
How can regulators and buyers protect themselves from substandard or falsified medicines sold online?
Apart from medicine, what changes to food, cities, or workplaces could affect obesity rates?
How can health information discuss body weight without shaming people?
How much should we trust projections, such as the 75 percent plateau, that go beyond observed data?
Drug companies fund most large trials of these medicines. How should readers weigh industry-funded evidence?
If you could design the next study on these drugs, what question would it answer, and how would you test it?

Language Focus: Reporting Numbers: Percent, Percentage Points, and Compared With

What it is: Results are usually reported as percentages of a starting value (14.9 percent of body weight). The difference between two percentages is measured in percentage points (from 8.0 percent to 6.5 percent is a fall of 1.5 percentage points, but a relative fall of about 20 percent). Comparisons with a control group use compared with, against, or versus.

Why writers use it: Confusing percent and percentage points changes the size of a result, and a relative figure can sound much larger than an absolute one. Saying what a result is compared with lets the reader judge the effect and avoid claims the data cannot support.

Examples from the reading:

“…lost an average of 14.9 percent of their body weight over 68 weeks on semaglutide, compared with 2.4 percent on placebo.”
“Headlines reported a 20 percent reduction in risk, which is the relative figure; the absolute difference was 1.5 percentage points.”
“…regained 11.6 percentage points of the 17.3 percent they had lost…”
“…64.8 percent of those without type 2 diabetes ended treatment within a year, compared with 46.5 percent of those with it.”

Practice task: Rewrite with compared with: “In the drug group, 4 percent had a heart attack. In the placebo group, 5 percent did.” Then state the absolute difference in percentage points and the relative difference in percent.

(Example answer: “In the drug group, 4 percent had a heart attack, compared with 5 percent in the placebo group: an absolute difference of 1 percentage point, or a relative reduction of 20 percent.”)

Recommended Resources

WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity (World Health Organization, 2025). Read the WHO announcement of its first guideline on these medicines and its concerns about fair access.
New Study Finds That Stopping Weight-Loss Drugs Is Linked to Faster Regain Than Ending Diet Programmes (University of Oxford, 2026). A short news release on the BMJ review, with the regain rates explained in plain language.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (JAMA, 2023). The research paper behind the stopping trial; the Key Points box at the top is the quickest place to start.
Semaglutide Reduces Cardiovascular Events in Adults Who Are Overweight by 20%, Study Finds (The Pharmaceutical Journal, 2023). A news report on the SELECT trial, with a reader’s comment on relative and absolute risk.
Generic Semaglutide Launches in India After Patent Expiry, Prices Drop Sharply (South First, 2026). An Indian news report on the first generic launches, the companies involved, and the new prices.